



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade

This is the author's manuscript

Original Citation:

Availability:

This version is available http://hdl.handle.net/2318/1729046 since 2021-12-10T10:25:17Z

Published version:

DOI:10.1158/1078-0432.CCR-18-1390

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

1 Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease

2 in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

- 3 Giuseppe Lo Russo¹*, Massimo Moro²*, Michele Sommariva³*, Valeria Cancila⁴*, Mattia Boeri²,
- 4 Giovanni Centonze², Simona Ferro⁵, Monica Ganzinelli¹, Patrizia Gasparini², Veronica Huber⁵,
- 5 Massimo Milione⁶, Luca Porcu⁷, Claudia Proto¹, Giancarlo Pruneri^{6,8}, Diego Signorelli¹, Sabina
- 6 Sangaletti⁹, Lucia Sfondrini³, Chiara Storti³, Elena Tassi^{10,11}, Alberto Bardelli^{12,13}, Silvia
- 7 Marsoni^{12,14}, Valter Torri⁷, Claudio Tripodo⁴, Mario Paolo Colombo⁹, Andrea Anichini¹⁰, Licia
- 8 Rivoltini⁵, Andrea Balsari^{3#}, Gabriella Sozzi^{2#§}, Marina Chiara Garassino^{1#}
- ¹Thoracic Oncology Unit, Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale
 dei Tumori, Milan (Italy)
- ²Tumor Genomics Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei
 Tumori, Milan (Italy)
- ¹³ ³Department of Biomedical Sciences for Health, University of Milan, Milan (Italy)
- ⁴Tumor Immunology Unit, Department of Health Sciences, Human Pathology Section, University
- 15 of Palermo, Palermo (Italy)
- ⁵Immunotherapy of Human Tumors Unit, Department of Research, Fondazione IRCCS Istituto
- 17 Nazionale dei Tumori, Milan (Italy)
- ⁶Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei
- 19 Tumori, Milan (Italy)
- ⁷Computational Statistics Unit, Department of Oncology, IRCCS Istituto di Ricerche
 Farmacologiche Mario Negri, Milano (Italy)
- ⁸ Dipartimento di Oncologia ed Emato-Oncologia, University of Milan, Milan (Italy)
- ⁹Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei
- 24 Tumori, Milan (Italy)

- ¹⁰Human Tumors Immunobiology Unit, Department of Research, Fondazione IRCCS Istituto
- 26 Nazionale dei Tumori, Milan (Italy)
- ¹¹Experimental Hematology Unit, IRCCS San Raffaele Scientific Institute, Milano (Italy)
- ¹²Candiolo Cancer Institute-FPO, IRCCS, Candiolo (Italy)
- ¹³ Department of Oncology, University of Torino, Candiolo (Italy);
- 30 ¹⁴IFOM, Istituto Firc di Oncología Molecolare, Milan Italy
- 31
- 32 *These Authors contributed equally at this work
- [#]These Authors contributed equally at this work as Senior Authors
- 34 [§] Corresponding author
- 35
- 36 **Running title:** ICI induce HP through FcR triggering on macrophages
- 37 Keywords: Hyperprogression; Non-small cell lung cancer; Immune checkpoint inhibitor;
- 38 macrophages; Fc Receptor;
- **Financial support:** This work was supported by Italian Ministry of Health (5 x 1000 Funds 2014)
- 40 (PI: Marina Chiara Garassino), by AIRC (Associazione Italiana per la Ricerca sul Cancro) (Grant
- 41 Id:15190, PI: Andrea Balsari; Grant Id: 18812, PI: Gabriella Sozzi; Grant id:17431 PI:Andrea
- 42 Anichini; Grant Id: 10137, PI: Mario P. Colombo), by EU project Horizon2020-686089 -
- 43 PRECIOUS (PI: Licia Rivoltini), by Italian Ministry of Health (Grant Id: GR-2013-02355637, PI:
- 44 Sabina Sangaletti). E. Tassi was supported by a fellowship from Fondazione Beretta-Berlucchi.
- 45
- 46
- 47
- 48
- 49

50 Corresponding Author:

- 51 Dr. Gabriella Sozzi
- 52 Tumor Genomics Unit, Department of Research,
- 53 Fondazione IRCCS Istituto Nazionale dei Tumori,
- 54 Via Giacomo Venezian 1, 20133 Milan (Italy)
- 55 Tel. +390223902232; +393480199805
- 56 Fax. +390223902928
- 57 e-mail: gabriella.sozzi@istitutotumori.mi.it
- 58

59 Disclosure of Potential Conflicts of Interest

A.A. has received travel and accommodation expenses and institutional research funding from
Bristol-Myers-Squibb; L.R. is being involved in scientific advisory boards, dissemination events
and teaching programs for Bristol Meyer Squibb, Novartis, AstraZeneca, Merck and Pfizer; M.C.G
is Advisory Board member of Bristol Meyer Squibb, MSD, Roche, Astra Zeneca, Novartis and
Steering Committee member of MSD. All the other Authors declare no potential conflicts of
interest.

- **Body text word count** = 4131 words
- 67 Abstract word count = 249 words
- **Figures and tables** = 5 (5 Figures, 0 Tables)
- 69 Supplementary Data: 5 (1 Supplementary Materials and Methods, 1 Supplementary Tables, 3
- 70 Supplementary Figures)
- 71 **References** = 31

73 ABSTRACT

<u>Background:</u> Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a
 subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinico-pathological
 features nor biological mechanisms associated with HP have been identified.

Methods: Among 187 patients with non-small cell lung cancer (NSCLC) treated with ICI at our Institute, cases with HP were identified according to clinical and radiological criteria. Baseline histological samples from patients treated with ICI were evaluated by immunohistochemistry (IHC) for myeloid and lymphoid markers. T-cell deficient mice, injected with human lung cancer cells and patient-derived xenografts (PDXs) belonging to specific mutational subsets, were assessed for tumor growth after treatment with antibodies against mouse and human programmed death receptor-1 (PD-1). The immune microenvironment was evaluated by flow cytometry and IHC.

Results: Among 187 patients, 152 were evaluable for clinical response. We identified 4 categories: 84 85 32 cases were defined as Responders (21%), 42 patients with Stable Disease (27.7%), 39 cases defined as Progressors (25.7%) and 39 patients with HP (25.7%). Pre-treatment tissue samples from 86 all patients with HP showed tumor-infiltration by M2-like CD163⁺CD33⁺PD-L1⁺ clustered 87 epithelioid macrophages. Enrichment by tumor-associated macrophages (TAM) was observed, even 88 in tumor nodules from immunodeficient mice injected with human lung cancer cells and with 89 90 PDXs. In these models, tumor growth was enhanced by treatment with anti-PD-1, but not by anti-91 PD-1 F(ab)₂-fragments.

92 <u>Conclusions:</u> These results suggest a crucial role of TAM reprogramming, upon Fc receptor
 93 engagement by ICI, eventually inducing HP and provide clues on a distinctive immunophenotype
 94 potentially able to predict HP.

96 STATEMENT OF TRANSLATIONAL RELEVANCE

97 Hyperprogressive disease in lung cancer and other tumors is an urgent clinical issue reaching 1 out of 5 patients treated with ICI, affecting their prognosis and leading to death in a very short time. As 98 99 the use of immunotherapy increases in the clinic, it is important to understand the intricacies of this new treatment option in order to optimize treatment approaches. Data already published in the field 100 mainly focused on adaptive immunity without finding any characteristics to predict a priori the 101 102 phenomenon. Our preclinical findings underline the role of innate immunity in mediating hyperprogression via Fc/FcR triggering on macrophages by anti-PD1 antibody. Accordingly, all 103 patients with HP showed tumor-infiltration by M2-like CD163⁺CD33⁺PD-L1⁺ clustered epithelioid 104 105 macrophages. These results, pointing to the involvement of innate immune cells in HP, provide new insights into the still unknown mechanisms behind a clinical conundrum. 106

108 **INTRODUCTION**

The advent of immune checkpoint inhibitors (ICI) has radically changed the paradigm of care for 109 patients with non-small cell lung cancer (NSCLC). Several agents are now approved in the 110 treatment of NSCLC based on their superiority over chemotherapy (1,2). Immunotherapy with 111 antibodies targeting either the programmed death receptor 1 (PD-1) or its ligand (PD-L1) may 112 provide long-term benefits in approximately 20% of patients (2). However, in a subset of patients, 113 ICI paradoxically accelerates tumor growth, a phenomenon known as hyperprogression (HP) (3–6). 114 115 Studies have estimated that the prevalence of HP in patients with different cancer histotypes treated with ICI may range between 9% and 29% (3-6). No significant histopathological and molecular 116 features capable of predicting a priori HP have been identified, with the partial exception of rare 117 MDM2 amplification and epidermal growth factor receptor (EGFR) mutations (5). These 118 observations have ignited an international debate regarding whether HP is a true phenomenon or 119 only representative of a subset of patients with a particularly worse prognosis. 120

121 In the tumor microenvironment, the effector functions of innate immune cells may be blunted by the PD-1 receptor, as observed for T lymphocytes, suggesting that these innate cells are another 122 potential target for ICI (7–9). Accordingly, it has been demonstrated that anti-PD-1 antibody can 123 exert antitumor activity in immunodeficient mice via natural killer (NK) cells (8). Conversely, it has 124 been demonstrated that, in PD-1^{-/-} NK cells or in NK cells pre-treated with anti-PD-1 antibody, the 125 production of lytic molecules such as perforins and granzymes is decreased (10). Moreover, tumor-126 infiltrating dendritic cells (9) and monocytes (11) are reported to release the immunosuppressive 127 cytokine interleukin-10 upon anti-PD-1 treatment. Therefore, it is possible to hypothesize that in 128 129 some circumstances, PD-1 blockade might exacerbate immunosuppression upon interaction with innate immune cells. 130

131 The aim of this study was to investigate, at the clinical and pathological level, the phenomenon of132 HP in NSCLC patients and to evaluate the role of innate immunity during ICI treatment. To

- eliminate the interference of T lymphocytes we exploited cell lines and patient derived xenografts
- 134 (PDXs) transplanted in immunodeficient mice.

136 MATERIAL AND METHODS

137 Clinical Series

Medical records, radiological findings, and available tumor specimens were collected from patients 138 with NSCLC treated with ICI at the Thoracic Unit of the Istituto Nazionale dei Tumori, Milan, 139 Italy, from July 2013 to December 2017. The study complied with the Declaration of Helsinki and 140 was done in accordance with good clinical practice guidelines. All samples were obtained according 141 142 to the Internal Review and the Ethics Boards of the Istituto Nazionale Tumori of Milan and all patients provided informed consent. All experimental protocols were approved by the Ethics Boards 143 of the Istituto Nazionale Tumori of Milan (Int 22/15). Radiological evaluation (computed 144 145 tomography scan with or without brain magnetic resonance imaging) was performed at treatment initiation and every 8 weeks thereafter. Considering that criteria to define patients with HP 146 described by previous authors (3-6) are applicable only in advanced lines, our multidisciplinary 147 148 team (oncologists, pneumologists, radiologists, and thoracic surgeons) created institutional clinical and radiological criteria designed to identify patients with HP also in first line treatment. Patients 149 with HP or those patients defined as P were classified according to predefined criteria as follows: i) 150 Time-to-treatment failure < 2 months (Time to treatment failure is defined as the time from the start 151 of treatment with ICI to ICI discontinuation for any reason, including progression, patient 152 preference, toxicity or death); ii) Increase of $\geq 50\%$ in the sum of target lesions major diameters 153 between baseline and first radiological evaluation; iii) Appearance of at least two new lesions in an 154 organ already involved between baseline and first radiological evaluation; iv) Spread of the disease 155 156 to a new organ between baseline and first radiological evaluation; v) Clinical deterioration with decrease in ECOG performance status ≥ 2 during the first 2 months of treatment. 157

Patients who fulfilled at least three of the clinical/radiological criteria were defined as exhibiting
HP, while patients with RECIST 1.1 progressive disease as best response without fulfilling at least
three criteria were defined as P patients. All R patients and SD patients were classified according to

- their RECIST 1.1 best response. Only patients who underwent at least two cycles of ICI treatmentwere included in the present analysis.
- 163

164 Immunohistochemistry

165 Immunohistochemistry was carried out on Formal-fixed Paraffin embedded human or PDX tissue 166 sections as described in Supplementary materials and methods. All the slides were analyzed under a 167 Zeiss Axioscope-A1 equipped with fluorescence module and microphotographs were collected 168 using a Zeiss Axiocam 503 Color with the Zen 2.0 Software (Zeiss, Oberkochen DE). All markers 169 were scored according to the percentage of immunoreactive cells out of the total cellularity.

170

171 Animals Studies

All xenograft experiments were undertaken using 8- to 9-week-old female athymic nude or SCID 172 mice (Charles River Laboratories, Calco, Italy). Human NSCLC cell line H460 tumor-bearing 173 athymic nude mice were treated i.p. or peri-tumorally (p.t.) with either 200 µg of monoclonal 174 antibody anti-mouse PD-1 (clone RMP1-14, BioXCell) or saline, and with either p.t. anti-PD-1 175 F(ab)₂ or isotype control. Experiments were carried out in groups of four SCID mice, bearing a 176 PDX sample or a cell suspension (10⁵ cells for H460 and PC9 xenograft experiments) in each flank. 177 Mice were treated twice weekly with an i.p. injection of 10 mg/kg Nivolumab (Opdivo, Bristol-178 Myers Squibb) or Nivolumab F(ab)₂ fragments. Mice were maintained in the Animal Facility of the 179 Fondazione IRCCS Istituto Nazionale dei Tumori. Animal experiments were authorized by the 180 Institutional Animal Welfare Body and the Italian Ministry of Health, and performed in accordance 181 with National law (D.lgs 26/2014) and Guidelines for the Welfare of Animals in Experimental 182 Neoplasia (12). At the end of each experiment, tumors were harvested for subsequent analyses. 183

184

185 Statistical Analysis

Distribution of continuous and categorical biomarkers was summarized by the median as a measure of central tendency and absolute frequencies, respectively. The Cochran–Mantel–Haenszel chisquare test was used to detect statistical association (i.e. P < 0.05) in univariate analysis. The median and interquartile range (IQR), follow up was estimated using the reverse Kaplan-Meier method.

192 **RESULTS**

193 Clinical and Pathological Evidence in Patients with Advanced NSCLC Treated with ICI

From July 2013 to December 2017, 187 patients with advanced NSCLC received treatment with ICI 194 at the Thoracic Unit of the Medical Oncology Department at the Istituto Nazionale dei Tumori, 195 Milan, Italy, and 152 patients were evaluable for response. We identified 4 categories: Responders 196 (R, 32 cases, 21%), patients with Stable Disease (SD, 42 cases, 27.7%), Progressors (P, 39 197 cases, 25.7%), and patients with HP (39 cases, 25.7%). Patients' characteristics are described in 198 Supplementary Table S1. In this population, after a median follow-up of 32.7 (IQR 15.1-39.6) 199 months, 108 out of 152 patients (71%) died. Median (95% CI) Overall Survival (OS) in the overall 200 201 population was 11.9 (95% CI 8.8-15.5) months.

If we restrict the analysis to patients with HP, median OS significantly decreased to 4.4 (95% CI

203 3.4-5.4) months as compared to 17.7 (95%CI 13.4 -24.1) in non HP patients. Median OS was 8.7

204 (95% CI 5.3-13.4), 17.7 (95% CI 12.7-25.5) and not reached in P, SD and R patients, respectively.

Supplementary Table S2 shows the differences between P and HP according to our criteria described in the Materials and Methods section. Of 187 patients, 64 were diagnosed in other centers and could not be included in the present histopathological and molecular analysis. Of the remaining 123, 35 patients (11 with HP and 24 without HP) were evaluable for response and had tissue samples suitable for a wide immunohistochemical characterization and gene expression analysis. Patients' characteristics of the extensively analyzed 35 samples resembles the clinical characteristics of the whole treated population

Immunohistochemical analysis was performed to assess the presence and distribution of tumorinfiltrating immune elements. The immunophenotype of 11 patients with HP was compared to that of 24 patients without HP (6 P, 11 SD and 7 R). No significant differences were observed among all the clinical classes of patient with respect to the subsets of tumor-infiltrating T lymphocytes (TILs), evaluated by the density of CD3⁺, CD4⁺, and CD8⁺ lymphocytes and FOXP3⁺ regulatory T cells (Tregs). In addition, no differences were detected between classes of patient in the numbers of

CD138⁺ plasma cells (PCs), CD123⁺ plasmacytoid dendritic cells (pDCs), peritumoral and stromal myeloperoxidase (MPO)⁺ myeloid cells, CD163⁺ macrophages, CD33⁺, PD-1 and PD-L1⁺ immune cells. However, MPO⁺ myeloid cells within the tumor were directly correlated (P= 0.0497) and PD-L1 expression in tumor cells was inversely correlated (P= 0.0457) with HP. Furthermore, a statistical trend was shown for the M2 macrophage/myeloid derived suppressor cells marker, Arginase-A I (ArgI) on peritumoral immune cells (P=0.0666) (Supplementary Table S3).

224 Gene expression profile (GEP) analysis of pre-treatment tumors did not show any relevant features except for under-expression of pathways related to proliferative activity and cell metabolism in 225 patients experiencing HP after ICI (Supplementary Figures S1A and S1B). The analyses of selected 226 227 genes representative of immune subsets by RT-qPCR revealed overexpression of the CD274 gene, encoding for PD-L1, as the only significant marker in R patients (Supplementary Figure S1C). 228 Fluorescence in situ hybridization of MDM2 and MDM4 genes, carried out on in a cohort of 30 229 230 FFPE NSCLC tissue derived from 11 patients with HP and 17 patients without HP, revealed the presence of 3 amplified tumors (2 MDM2, 1 MDM4) in patients with HP and 6 amplified tumors (4 231 MDM2, 1 MDM4 and 1 MDM2 and MDM4) in patients without HP (Supplementary Figure S2). 232

Notably, we noticed that, in some cases, CD163⁺ tumor-infiltrating macrophages showed 233 epithelioid morphology (alveolar macrophage-like) with the tendency to form dense clusters within 234 235 neoplastic foci (Figure 1A). In these cases, the same cells were found to co-express CD33 and PD-L1 (Figure 1B and Figure 2). Such a peculiar morphology, aggregation, and immunophenotype 236 (CD163⁺CD33⁺PD-L1⁺) of macrophages, which we define "complete immunophenotype", was 237 observed in all patients with HP and found to be statistically significant versus patients without HP 238 (P<0.0001) (Supplementary Tables S4 and S5). This complete immunophenotype was also 239 240 observed in one P patient, two patients with SD, and one R patient (Supplementary Table S5). All other cases experiencing treatment response with stable or slowly progressive disease either lacked 241 the presence of epithelioid macrophages or showed loose clustering, or lacked some of the above 242 243 markers (mainly CD33⁻ and/or PD-L1) (Figure 1C and 1D).

Anti Mouse PD-1 Antibody Induces Tumor Progression in Athymic Mice 244

Histopathological analyses showed the presence of clustered CD163⁺CD33⁺PD-L1⁺ epithelioid 245 macrophages as a distinctive trait in tumors with HP. Therefore, we sought to test whether 246 macrophages are involved in the detrimental effects associated with anti-PD-1 therapy in preclinical 247 models. Athymic nude mice implanted with human H460 NSCLC cell line were treated either 248 intraperitoneally (i.p.) (Figure 3A) or peritumorally (p.t.) (Figure 3B) with anti-PD-1 antibody 249 250 (clone RMP1-14) or saline. Anti-PD-1 treatment increased tumor growth compared with the control group, regardless of route and schedule of treatment (Figure 3A and 3B). Anti-PD-1 treatment was 251 also associated with a significant increase in CD45⁺ leukocyte infiltration at the host-tumor 252 253 interface, evaluated by immunohistochemistry (IHC) (Figure 3C). Such an increase was mainly due to increasing numbers of intratumoral macrophages (F4/80⁺ cells) and Arginase-I⁺-expressing cells, 254 whereas the density of B lymphocytes (CD45R/B220⁺), granulocytes (Gr-1⁺) and NK (NKp46⁺) 255 256 cells was comparable to the control group (Figure 3C). Of note, Arginase-I was also consistently expressed by the complete immunophenotype intra-tumor macrophages characterizing patients with 257 HP (Figure 1E). Tumor-associated macrophages (TAMs) can express PD-1 and the blocking of this 258 receptor restores antitumor functions (7). Thus, the detrimental boost in tumor growth may not be 259 ascribed to such receptor blockade, but rather to the Fc domain of the antibody which is reported to 260 261 modulate anti-PD-1 antibody functional activity (13). Accordingly, the same experiments were performed using anti-PD-1 F(ab)₂ fragments. The lack of the Fc portion abrogated the increase in 262 tumor growth observed with the whole antibody (Figure 3D). 263

Anti Human PD-1 Antibody (Nivolumab) Induces Tumor Progression of PDXs in SCID Mice 264

To exclude a direct involvement of PD-1 expression in immune cells, we treated severe combined 265 immunodeficient (SCID) mice with anti-human PD-1 (Nivolumab) which does not cross-react with 266 the murine counterpart (Supplementary Figure S3A). Since a link between HP and EGFR 267 mutational status has been proposed by Kato et al. (5), we compared two NSCLC PDXs, with and 268 without EGFR mutation: PDX302 (P53^{C135Y}, EGFR^{L858R}, KRAS^{WT}, APC^{WT}) versus PDX305 269

270 (P53^{WT}, EGFR^{WT}, KRAS^{G12C}, APC^{R1114L}). On PDXs, before treatment, fluorescence-activated cell 271 sorting (FACS) analysis with human anti-PD1 antibody showed expression of PD-1 receptor on a 272 subset of tumor cells (around 1% PD-1⁺ cells, Supplementary Figure S3B). In addition, IHC 273 analysis showed that F4/80⁺ epithelioid/monocytoid elements, aggregated in clusters resembling 274 those identified in patients with HP, were appreciable only in PDX302 (Supplementary Figure 275 S3C).

SCID mice carrying subcutaneous PDX302 (n = 8), but not PDX305 (n = 8), showed a significant increase in tumor growth rate compared with controls following twice weekly treatment with Nivolumab (Figure 4A). FACS analysis in lungs of PDX302 bearers showed increased cancer cell dissemination in Nivolumab-treated mice but not in controls ($3.88\pm1.99\%$ vs. $0.87\pm0.33\%$, P =0.0286, respectively) (Figure 4B), whereas no differences were detected in PDX305 bearers (data not shown).

282 FACS analysis was also performed on primary tumors for characterization of different myeloid subsets (CD11b, Ly6G, Ly6C, F4/80) and NK cells (CD49b). In PDX302-bearing mice, an increase 283 in CD11b⁺F4/80^{high} macrophages was observed in the Nivolumab-treated group versus controls 284 (Supplementary Figure S3D), whereas no significant changes occurred in other immune 285 subpopulations. Accordingly, IHC analysis performed on the same tumors revealed accumulation of 286 287 macrophages and ArgI⁺-expressing cells (Figure 4C and Supplementary Figure S3E). Notably, in PDX302 the F4/80⁺ epithelioid/monocytoid clusters were enriched in Nivolumab-treated tumors 288 (Figure 4C). 289

Overall, these data indicate that, in the *EGFR*-mutated PDX302-bearing mice, Nivolumab triggers a detrimental effect characterized by increased tumor growth, lung dissemination and the accrual of macrophages, most likely M2.

To further confirm the detrimental effect induced by Nivolumab in other preclinical models, PDX111 (P53^{C242X}, KRAS^{G12V}, CDKN2A ^{E69X}, CTNNB1^{T41I}), PDX220 (wild type for all tested genes), H460 (KRAS^{Q61H}, STK11^{Q37*}), and PC9 (EGFR^{L858R}, EGFR^{E746_A750del}, CDKN2A^{G67V}) were

xenografted in SCID mice. All tested models showed low levels of PD1-expression on tumor cells (ranging from 0.6 to 4%, Supplementary Figure S3B). As with PDX302, an increase in tumor growth was observed in H460- and PC9-bearing mice after Nivolumab treatment. PDX111 tumors showed a variable response, whereas tumors in PDX220- and PDX305-bearing mice showed no response to Nivolumab (Figure 4D).

To reinforce the role of the Fc domain of the antibody in boosting tumor growth, PDX302-bearing 301 302 SCID mice were treated with Nivolumab-F(ab)₂ fragments. No HP-like growth was observed (Figure 4E) whereas in the same experiment mice treated with the entire antibody showed HP-like 303 growth, dissemination to lung (Figure 4F) and regional (iliac) lymph node metastases (Figure 3G). 304 In the group pretreated with clodronate, which reduces F4/80⁺ macrophages, impaired Nivolumab-305 induced tumor growth was observed (Figure 4E). The F4/80⁺ macrophages also stained for CD206 306 that marks M2-like subsets and aggregated in fibrotic-like areas in Nivolumab- but not in 307 308 Nivolumab F(ab)₂-treated tumors. In the latter less fibrotic areas than in control mice were observed (Figure 4H). 309

These results suggest that HP is sustained by Nivolumab interaction with M2-like macrophages,
most likely via Fc-Fcγ receptor binding (Figure 5).

313 **DISCUSSION**

Although ICI have changed the paradigm of care for patients with NSCLC, an in-depth examination 314 of the Kaplan-Meier curves from the CheckMate-026 (14), CheckMate-057 (15), CheckMate-227 315 (16), and KEYNOTE-042 (17) trials showed an excess of disease progression and death in the 316 immunotherapy treatment arms compared with chemotherapy in the first 3 months of treatment. 317 This was also underscored by the European Medicines Agency in response to the appraisal for the 318 319 second-line use of Nivolumab in non-squamous histologies (http://www.ema.europa.eu/docs/en GB/document library/EPAR -320

Product_Information/human/003985/WC500189765.pdf). Furthermore, the benefit of ICI in trials 321 322 conducted in never smokers and in patients with EGFR mutation-positive or Anaplastic Lymphoma Kinase (ALK)-mutation-positive NSCLC seems unclear (1,2,5,14,15). The four most important 323 papers on the HP topic showed prevalence rates ranging from 9% to 29% throughout tumor types, 324 325 including NSCLC (3-6). In all these papers, the ratio of the tumor growth rates before and during ICI treatment was used to identify HP, although with slightly different cut-offs. None of these 326 327 studies defined pathological features able to predict HP, although MDM2/4 amplification and EGFR alterations were proposed to be associated (5). However, we did not find any significant difference 328 in the frequency of MDM2/4 amplification between patients with and without HP, and the role of 329 330 EGFR cannot be discussed due to the low number of EGFR-mutated patients included in our case series (Supplementary Table S1) 331

Our definition of HP is different from that used in the above-mentioned studies, where radiological imaging before, at the start and after ICI is needed to identify HP. However, in clinical practice all these radiological evaluations are often unavailable, and as a consequence, the criteria used in literature are unable to classify patients with HP considering that ICI are starting to be widely used as first line therapy. Furthermore, both Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and Immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) criteria, used in the reported analyses, considered only changes in tumor size and did not take into account non-target lesions, such as lymphangitis and pathological lesions under 10 mm. In addition, functional and clinical aspects, such as deterioration in performance status, were not considered. Therefore, we decided to include both clinical and radiological criteria to identify patients with HP in our series. These proposed criteria might overestimate the real fraction of patients experiencing HP; for these reasons, a clinical trial is ongoing within our Institute to properly validate the criteria and thereby obtain the true rate of HP as well as the distinctive immunophenotype.

Nivolumab-treated cell lines and PDX-bearing SCID mice mirrored the clinical observation of HP 345 following treatment with ICI. Interestingly, patients and mice classified with HP share a similar 346 tumor immunophenotype. Indeed, the population of F4/80⁺CD206⁺Arginase-A1⁺ cells emerging 347 from PDXs with HP matches macrophage features of the human counterpart (Figures 1A, 4C, 4H 348 and Supplementary Figure S3C). M2-like macrophages were preferentially associated with fibrotic 349 350 foci in PDXs that experience HP-like tumor growth after PD-1 blockade. The recruitment of these myeloid cells may promote a peculiar cancer-associated innate response that may affect tumor 351 growth. Indeed, Knipper at al. described a cross-talk between myeloid cells and fibroblasts 352 promoting skin fibrosis that could provide proliferative and pro-survival signals in cancer cells (18). 353 354 Prominent mitotic figures can be consistently identified in Nivolumab-treated tumor foci embedded 355 in a fibrotic stroma. In human samples, the accumulation of these cells is apparently unrelated to the extent and distribution of tumor-infiltrating T-cell populations. 356

The role of the innate immune system in mediating the effects of ICI is now clearly emerging. Cells of myeloid origin present in the tumor microenvironment decrease the effects of ICI via PD-L1 expression (19), by "stealing" anti-PD-1 antibody from the membrane of T lymphocytes that return to anergy (20) or by secreting immunosuppressive molecules (21). Our study provides novel evidence of negative immuno-regulatory role exerted by PD-L1⁺ macrophages enriched at tumor site under treatment with ICI. Pre-treatment lesions from all patients classified as HP showed tumor infiltration by clustered epithelioid macrophages characterized by a CD163⁺CD33⁺PD-L1⁺ profile.

Interestingly, CD163⁺ PD-L1⁺ macrophages represent a common immune landscape for different 364 tumors. PD-L1⁺ macrophages have been recently described to accumulate in tight clusters at the 365 tumor invasive margin in NSCLC (22). Macrophages expressing both PD-L1 and the "M2" marker 366 CD163 have been described in MSI-colorectal cancer (23), triple-negative breast cancer (24), 367 gastric and cervical cancer (25,26). In some of these studies, the presence of PD-L1⁺ macrophages 368 has been associated with poor prognosis (24,26) and/or with immunosuppressive function through 369 370 IL-10 production (27). In addition, the concurrent expression of CD163, CD33, and PD-L1 has been recently described in alveolar macrophages from acute respiratory distress syndrome patients, a non 371 oncological condition present in 10% of subjects admitted to intensive care units (28). In this 372 373 regard, we observed an increased infiltration of M2 macrophages after anti-PD-1 administration, 374 providing evidence for their involvement in determining HP. TAMs can also express PD-1 that, if neutralized, can restore M1-like properties (7). This likely excludes blockade of PD-1 signaling in 375 376 our models that remain rather oriented to M2. Therefore, we examined the possibility of FcR engagement as a modulator of anti-PD-1 activities (13). Upon testing the F(ab)₂ moiety in 377 378 comparison to whole Ab, we have shown that Nivolumab without the Fc domain no longer induces HP-like disease in our models. 379

The anti-mouse PD-1 clone RMP1-14, utilized for the treatment of tumor-bearing athymic mice, is 380 381 a rat immunoglobulin IgG2a reported to interact with the mouse inhibitory receptor, FcyRIIb (13). FcyRIIb has been shown to be involved in dampening the immune response, and impairments in 382 FcyRIIb function are associated with an exacerbation of inflammatory processes (29). The anti-383 human PD-1 antibody Nivolumab is an IgG4 isotype with reduced binding affinity to activating 384 FcγRs, thereby avoiding antibody-dependent cell-mediated cytotoxicity on PD-1⁺ immune cells 385 (30). However, Nivolumab maintains the ability to bind to the inhibitory FcyRIIb receptor (13). 386 Therefore, we suggest a possible role of FcyRIIb in the detrimental effect associated with anti-PD-1 387 therapy. However, since both human IgG4 and rat IgG2a can bind at lower affinity to other FcRs, 388 389 the involvement of these receptors cannot be excluded. Further studies elucidating the involvement

of FcRs in the development of HP are required. Very recently, a report described PD-1 expression in one NSCLC case with HP and in one mouse NSCLC cell line. The latter treated with anti murine PD-1 Ab underwent accelerated tumor growth (31). This interesting and logical explanation of HP can't be totally supported by the low expression/prevalence of PD-1 on tumors and by $F(ab)_2$ experiments in mice. We found clusters of PD-1 expressing cells in 2 out of 11 patients with HP (data not shown) and in all xenografts and PDXs, although at low levels (0.6 - 4%) and with no correlation with HP-like progression.

In conclusion, the ongoing debate regarding whether HP is a true phenomenon or only 397 representative of patients with a particularly worse prognosis is confirmed in our preclinical models, 398 399 where ICI are able to boost tumor growth in a manner akin to the clinical observations of HP in patients with NSCLC. Our results suggest that FcR triggering of clustered epithelioid macrophages 400 with a specific immunophenotype by ICI delivers a signaling cascade that promotes functional 401 402 reprogramming of these cells toward a more aggressive pro-tumorigenic behavior. This eventually induces HP in a subset of patients with distinctive immune and genetic profiles (depicted in Figure 403 404 5). Our analyses, for the first time, suggest a role of innate immunity in this process. A further prospective validation of the HP immunophenotype and its relationship with specific genotypes, as 405 well as the new proposed clinical criteria to classify HP, is ongoing. 406

407

408 Authors' Contributions

- 409 Conception and design: GS, MCG, ABardelli, SM, LR, AA, ABalsari
- 410 Development of methodology: VC, GC, SF, PG, CS
- 411 Acquisition of data: CT, MMilione, MB, MS, MMoro, GL, PG, MG, VH, CP, DS, ET, SS
- 412 Analysis and interpretation of data: CT, MMoro, MS, GL, GP, LP, VT, CP, DS, LS, SS
- 413 Writing, review and/or revision of the manuscript: ABardelli, SM, MS, MMoro, MG CP, DS, GL,
- 414 MPC, CT, GA, AA, ABalsari, LR, GS, MCG
- 415 Study supervision: MPC, GS, MCG, GA
- 416

417 Acknowledgments

- 418 The authors wish to thank the following individuals: Dr M. Figini for the production of Nivolumab-
- F(ab)₂; Dr L. De Cecco for GEP profiles; Dr M. Dugo for bioinformatic analyses; Mrs A. Cova and
 Dr A. Berzi for technical assistance; Dr A. Martinetti for biological sample collection; Dr E.
 Tagliabue for data discussion and interpretation; Dr G. Morello for her precious support in
 performing double-marker immunolocalization analyses, and Dr G. Apolone for continuous support
- 423 in the planning and execution of the study and for scientific writing. The authors would also like to
- 424 acknowledge the editorial assistance provided by Chris Cammack, a professional medical writer at
- 425 Ashfield Healthcare Communications, an Ashfield Company, part of UDG Healthcare plc426 (Tytherington, UK).

428 **REFERENCES**

- 1. Califano R, Kerr K, Morgan RD, Lo Russo G, Garassino M, Morgillo F, et al. Immune
- 430 Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. Curr Oncol Rep.
- 431 Current Oncology Reports; 2016;18.
- 432 2. Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in
 433 advanced non–small cell lung cancer. Cancer. 2018;124:248–61.
- 434 3. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al.
- 435 Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-
- 436 PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8.
- 437 4. Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al.
- 438 Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or
- metastatic head and neck squamous cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol.
 2017;28:1605–11.
- 441 5. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R.
- 442 Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with
- 443 accelerated growth rate. Clin Cancer Res. 2017;23:4242–50.
- 6. Ferrara R, Caramella C, Texier M, Valette CA, Tessonnier L, Mezquita L, et al.
- 445 Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients
- 446 (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO). Ann Oncol. Oxford
- 447 University Press; 2017;28:abstract 1306PD.
- 448 7. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1
- 449 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
- 450 Nature. Nature Publishing Group; 2017;545:495–9.
- 451 8. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell
- death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor
- 453 prognosis in digestive cancers. Oncogene. 2017;36:6143–53.

- 454 9. Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, et al. IL10 release
 455 upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res.
 456 2017;77:6667–78.
- 457 10. Solaymani-Mohammadi S, Lakhdari O, Minev I, Shenouda S, Frey BF, Billeskov R, et al.
 458 Lack of the programmed death-1 receptor renders host susceptible to enteric microbial
- 459 infection through impairing the production of the mucosal natural killer cell effector

460 molecules. J Leukoc Biol [Internet]. 2015;99:2–9.

11. Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, et al. Programmed death-1-

462 induced interleukin-10 production by monocytes impairs CD4 + T cell activation during HIV
463 infection. Nat Med [Internet]. Nature Publishing Group; 2010;16:452–9.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines
for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.12

13. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch J V. FcγRs Modulate the

467 Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell. Elsevier;
468 2015;28:285–95.

14. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab
in Stage IV or Recurrent Non–Small-Cell Lung Cancer. N Engl J Med. 2017;376:2415–26.

15. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus

472Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med.

473 2015;373:1627–39.

16. Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al.

- 475 Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl
- 476 J Med [Internet]. 2018;NEJMoa1801946.
- 17. Lopes G, Wu Y-L, Kudaba I, Kowalski D, Chul Cho B, Castro G, et al. Pembrolizumab
- 478 (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for
- advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) \geq 1%: Open-label,

480	phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36:suppl. abstr	. LBA4.

- 18. Knipper JA, Willenborg S, Brinckmann J, Bloch W, Maaß T, Wagener R, et al. Interleukin-4
- 482 Receptor α Signaling in Myeloid Cells Controls Collagen Fibril Assembly in Skin Repair.
- 483 Immunity. 2015;43:803–16.
- 484 19. Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, et al.
- 485 Immunosuppressive tumor-infltrating myeloid cells mediate adaptive immune resistance via
- 486 a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017;19:796–807.
- 487 20. Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, et al. In vivo
- 488 imaging reveals a tumor-associated macrophage mediated resistance pathway in anti PD-
- 489 1 therapy. Sci Transl Med. 2017;1–10.
- 490 21. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor
- 491 microenvironment : expect the unexpected. J Clin Investig. 2015;125:3356–64.
- 492 22. Lavin Y, Kobayashi S, Leader A, Amir E ad D, Elefant N, Bigenwald C, et al. Innate
- Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell
 [Internet]. Elsevier Inc.; 2017;169:750–765.e17.
- 495 23. Korehisa S, Oki E, Iimori M, Nakaji Y, Shimokawa M, Saeki H, et al. Clinical significance
- 496 of programmed cell death-ligand 1 expression and the immune microenvironment at the
- 497 invasive front of colorectal cancers with high microsatellite instability. Int J Cancer.
- 498 2018;142:822–32.
- Adams A, Vail P, Ruiz A, Mollaee M, McCue P, Knudsen E, et al. Composite analysis of
 immunological and metabolic markers defines novel subtypes of triple negative breast
 cancer. Mod Pathol. 2018;2:288–98.
- 502 25. Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, et al. Tumor-associated
- 503 macrophage infiltration is highly associated with PD-L1 expression in gastric
- adenocarcinoma. Gastric Cancer. Springer Japan; 2018;21:31–40.
- 505 26. Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, Van Der Velden J, Kenter GG, et al.

506		Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and
507		adenocarcinoma of the cervix. Mod Pathol [Internet]. Nature Publishing Group;
508		2016;29:753–63.
509	27.	Kubota K, Moriyama M, Furukawa S, Rafiul HASM, Maruse Y, Jinno T, et al.
510		CD163+CD204+ tumor-associated macrophages contribute to T cell regulation via
511		interleukin-10 and PD-L1 production in oral squamous cell carcinoma. Sci Rep [Internet].
512		Springer US; 2017;7:1–12.
513	28.	Morrell ED, Wiedeman A, Long SA, Gharib SA, West TE, Skerrett SJ, et al. Cytometry TOF
514		identifies alveolar macrophage subtypes in acute respiratory distress syndrome. JCI Insight
515		[Internet]. 2018;3:1–11.
516	29.	Roghanian A, Stopforth RJ, Dahal LN, Cragg MS. New revelations from an old receptor:
517		Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B). J
518		Leukoc Biol. 2018;1–12.
519	30.	Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in cancer: A combat
520		between tumors and the immune system; you win some, you lose some. Front Immunol.
521		2015;6:2–13.
522	31.	Du S, McCall N, Park K, Guan Q, Fontina P, Ertel A, et al. Blockade of Tumor-Expressed
523		PD-1 promotes lung cancer growth. Oncoimmunology. 2018;
524		
525		

527 FIGURE LEGENDS

528 Figure 1. Immunohistochemical analyses for CD163, PD-L1 and CD33 in representative

529 hyperprogressor and non-hyperprogressor cases.

(A) Representative microphotographs detailing the presence of macrophages displaying epithelioid 530 morphology and expression of CD163, PD-L1, and CD33 markers (defined as *complete phenotype*) 531 532 in four hyperprogressor cases. (B) Double immunofluorescence staining for CD163 (green) and PD-L1 (red) showing the co-expression of the two markers in epithelioid macrophages (arrows). (C) 533 Representative microphotographs detailing the presence of macrophages displaying epithelioid 534 morphology, variable clustering and the incomplete expression of the three CD163, PD-L1, and 535 CD33 markers (defining the complete phenotype of HP patients) in two cases of non-HP patients 536 (stable disease). (D) Representative microphotographs detailing the presence of myeloid elements 537 with non-epithelioid morphology (stellate or spindle-shaped cells) on CD163, PD-L1, and CD33 538 markers populating tumor infiltrates of non-HP patients (one stable disease and one response). (E) 539 Representative microphotographs relative to Arginase-A1 expression by clustered epithelioid 540 macrophages in four HP patients' infiltrates. Magnification 20x. 541

Figure 2. CD33, CD163, and PD-L1 co-localization in clustered macrophages with epithelioid morphology

Immunofluorescence panels from prototypical hyperprogressive disease infiltrates showing the colocalization of CD33, CD163, and PD-L1 in clustered macrophages with epithelioid morphology.
Three different combinations of double-marker stainings are shown. Green signal and red signal
correspond to Opal-520 and Opal-620 fluorophores, respectively. Original magnifications x100 and
x400.

549 Figure 3. Anti Mouse PD-1 Antibody Induces Tumor Progression in Athymic Mice

550 Athymic nude mice were xenografted with H460 lung cancer cell lines and treated i.p. (n=6 551 mice/group) (**A**) or p.t. (n=5 mice/group) (**B**) with 200 μ g of anti-mouse PD-1 blocking antibody 552 (red dots) or with vehicle (black dots). Red arrows indicate the days of anti-PD-1 antibody

treatment. Dots represent Mean ± SEM of tumor volume for each group. **P <0.01 by Mixed 553 554 Models ANOVA. (C) Representative immunohistochemistry images and quantification of leukocytes (CD45⁺), macrophages (F4/80⁺), Arginase-I⁺, B lymphocytes (CD45R/B220⁺), 555 granulocytes (Gr-1⁺) and NK (NKp46⁺) cells in the tumor microenvironment of H460 lung cancer 556 xenografts collected from the study illustrated in Figure 2B (p.t. experiment, n=5 mice/group). 557 Original magnification x20. *P <0.05, **P <0.01 by Mann-Whitney U test. (**D**) Athymic nude mice 558 559 were xenografted with H460 lung cancer cell lines and treated i.p. with 200 µg anti-PD-1 F(ab)₂ (blue dots) or with vehicle (black dots) (n=6 mice/group). Blue arrows indicate the days of anti-PD-560 1 antibody treatment. Dots represent Mean \pm SEM of tumor volume for each group. 561

Figure 4. Anti Human PD-1 Antibody (Nivolumab) Induces Tumor Progression of PDXs in SCID Mice

564


(A) PDX302 (P53C135Y, EGFRL858R, KRASWT, APCWT) and PDX305 (P53WT, EGFRWT,

565 KRASG13C, APCR1114L) samples were injected in both flanks of SCID mice (n = 4). Mice were 566 treated with 10 mg/kg i.p. Nivolumab (red dots) twice weekly from day 1 after tumor implant to the 567 end of the experiment. **P < 0.01 by mixed models ANOVA. (B) Analysis of tumor cells 568 disseminated to mice lungs. Mice lungs were analyzed by FACS, after tissue dissociation to single 569 cells, for the presence of human disseminated cells. Graphs indicate the percentage of human cells 570 in Nivolumab treated and control mouse lungs. *P < 0.05 (C) Representative images showing 571 F4/80+ cells with epithelioid/monocytoid elements aggregated in clusters in an untreated PDX302


model. (D) Dot plot summarizing the results of the effects of Nivolumab treatment in all tested PDX (PDX302, PDX305, PDX111, and PDX220) and xenograft models (H460 and PC9). Response rate was estimated as described in the Materials and Methods section. (E) PDX302 (P53C135Y, EGFRL858R, KRASWT, APCWT) samples were injected in both flanks of SCID mice (n = 4). Mice were treated with 10 mg/kg i.p. Nivolumab, Nivolumab F(ab)2 or clodronate plus Nivolumab twice weekly (once weekly for clodronate injection) from day 1 after tumor implant to the end of the experiment. *P < 0.05. (F) Analysis of tumor cells disseminated to mice


lungs. Mice lungs were analyzed by FACS, after tissue dissociation to single cells, for the presence 579 580 of human disseminated cells. Graphs indicates the percentage of human cells in Nivolumab-, Nivolumab F(ab)₂- or Clodronate plus Nivolumab treated and control mouse lungs. *P < 0.05581 compared to control; ${}^{\#}P < 0.05$ compared to Nivolumab-treated (G) Representative IHC images of 582 mouse iliac lymph nodes show tumor cell dissemination with the presence of a metastatic nodule 583 (indicated by the asterisk) only in Nivolumab-treated mice (H/E: hematoxylin/eosin staining; CK: 584 pan-cytokeratin staining). (H) H&E and Masson's trichrome staining showing the presence of 585 fibrotic areas with consistent matrix deposition in Untreated, Nivolumab- and Nivolumab F(ab)₂-586 treated representative cases. IHC analysis for CD206⁺ macrophages highlighting the enrichment in 587 588 macrophages in Nivolumab treated tumor. 589

Figure 5. Hypothesized mechanism through which macrophages and ICI are involved in determining HP



Downloaded from clincancerres.aacrjournals.org on September 23, 2018. © 2018 American Association for Cancer Research.









Figure 4





Clinical Cancer Research

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, et al.

Clin Cancer Res Published OnlineFirst September 11, 2018.

Updated version	Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-18-1390
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2018/09/11/1078-0432.CCR-18-1390.DC1
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2018/09/11/1078-0432.CCR-18-1390. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.